secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001641489-25-000051
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q2 net loss $6.0M; Phase 3 T1D trial randomized
----------------------------------------------------------------

- Net loss attributable to vTv shareholders of $6.0M ($0.92/share) vs $5.2M ($0.81/share) in Q2 2024.
- Cash and cash equivalents $25.9M at June 30, 2025, down from $36.7M at December 31, 2024.
- First patient randomized in Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes; topline data expected H2 2026.
- Appointed Michael Tung, MD, MBA as CFO in May 2025.
- USPTO allowed patent claims for crystalline salt form of cadisegliatin with term through 2041.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000051/0001641489-25-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000051/vtvt-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001641489-25-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer